RTD 64mg

Description

!!For Laboratory & Research Purposes Only !!

RTD 64mg is a research-grade triple-agonist peptide that targets three metabolic hormone receptors — Glucagon-Like Peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon. Eli Lilly developed the compound as an investigational treatment for weight loss, and in trials it is dosed once weekly via subcutaneous injection after reconstitution with bacteriostatic water.

How it Works: GLP-1, GIP & Glucagon

RTD produces weight loss by activating three metabolic receptors at once. Together, these receptors control how much you eat, how efficiently you process glucose, and how much energy you burn at rest.

1. GLP-1 receptor (appetite & satiety) — Slows gastric emptying and signals fullness to the hypothalamus, reducing hunger and meal size. Semaglutide uses this same pathway.
2. GIP receptor (insulin sensitivity & fat handling) — Enhances glucose-dependent insulin secretion and influences how adipose tissue stores and releases fat. GIP activity is thought to reduce the metabolic resistance that frequently stalls weight loss on GLP-1-only drugs.
3. Glucagon receptor (energy expenditure & lipolysis) — Stimulates hepatic fat oxidation and raises basal metabolic rate, so the body burns more calories at rest. Semaglutide and tirzepatide lack this mechanism.

Is it legal to buy in South Africa?

It is not a SAHPRA-registered medicine. All three actives fall under South Africa’s medicines-scheduling framework, and Ignite Muscles supplies it for research and educational purposes only. Any personal use should be discussed with a registered SA practitioner.